Scarlet Cardona

In a strategic move to expand access to its weight-loss drug, Eli Lilly has launched a new, more affordable version of Zepbound, priced at nearly half the price of its standard offering. The move is intended to make the drug more accessible to millions of patients worldwide, potentially transforming the obesity treatment landscape. The introduction of Zepbound at a reduced price comes at a time when demand for effective weight loss solutions is growing, but the high cost of treatment remains a barrier for many. By reducing the price, Eli Lilly not only aims to reach a wider audience, but…

In a recent announcement, Sesame Health Marketplace introduced a new clinical weight-loss initiative aimed at providing consumers with affordable access to compounded versions of the widely acclaimed obesity treatment Wegovy, priced at $249 per month. This innovative platform facilitates direct interactions between patients and healthcare providers to schedule and pay for medical visits, bypassing traditional insurance processes. The move includes the addition of the compound semaglutide, the lead component of Wegovy and Novo Nordisk’s diabetes treatment Ozempic, to its platform. This addition is especially timely given the current market shortage of several leading branded drugs. Sesame’s portfolio already includes a…